ArticleJournal of blood medicine2019
Cold agglutinin disease: current challenges and future prospects.
Article in Journal of blood medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.Blood advances · 2019Pooled it
- Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial.American journal of hematology · 2026Trial
- Trial
- Cold agglutinin disease: pathophysiology, diagnosis, and the evolving therapeutic landscape.Blood research · 2026Review
- Cold agglutination as a pivotal diagnostic clue for Waldenström macroglobulinemia: A rare case report with diagnostic and therapeutic insights.Experimental and therapeutic medicine · 2026Article
- Cyclosporine in hematological disorders: mechanisms, clinical practice and emerging advances.Annals of hematology · 2026Review
- A diagnostic pitfall in cold agglutinin disease: KMT2D-mutated CAD-associated lymphoproliferative disorder with a CLL-like immunophenotype.Oxford medical case reports · 2026Article
- Occurrence of Cold Agglutinin Disease among Patients with Autoimmune Hemolytic Anemia: A Hungarian Single-Center Experience.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Article
- The impact of chemoimmunotherapy on primary cold agglutinin disease and Waldenström macroglobulinemia-associated cold agglutinin syndrome.Frontiers in medicine · 2026Article
- A Rare Combination: Cold Agglutinin Disease Followed by Waldenström Macroglobulinemia-A Case of Early Treatment Response.Diagnostics (Basel, Switzerland) · 2025Article
- [Cold agglutinin disease (CAD)].Innere Medizin (Heidelberg, Germany) · 2025Review
- Cryoproteins in Non-HCV-Related Autoimmune Disorders: A Serious Cold-Induced Problem.Diagnostics (Basel, Switzerland) · 2025Review
- Incidental Cold Agglutinins in Lung Transplant Recipients.Transplantation direct · 2025Article
- Anesthesia for Urgent Gastroscopy in Cold Agglutinin Disease: A Case Report and Literature Review.Cureus · 2025Article
- Efficacy of sutimlimab for cold agglutinin disease in a patient on chronic hemodialysis.CEN case reports · 2025Article
- Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016-2023.PloS one · 2025Article
- Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy.Current oncology reports · 2024Review
- The common variable immunodeficiency IgM repertoire narrowly recognizes erythrocyte and platelet glycans.The Journal of allergy and clinical immunology · 2024Article
- Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International journal of molecular sciences · 2024Review
- Management of autoimmune haemolytic anaemia in low-to-middle income countries: current challenges and the way forward.The Lancet regional health. Southeast Asia · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cold agglutinin disease (CAD) is a complement-dependent, classical pathway-mediated immune hemolytic disease, accounting for 15-25% of autoimmune hemolytic anemia, and at the same time, a distinct clonal B-cell lymphoproliferative disorder of the bone marrow. The disease burden is often high, but not all patients require pharmacological treatment. Several therapies directed at the pathogenic B-cells are now available. Rituximab plus bendamustine or rituximab monotherapy should be considered first-line treatment, depending on individual patient characteristics. Novel treatment options that target the classical complement pathway are under development and appear very promising, and the C1s inhibitor sutimlimab is currently being investigated in two clinical Phase II and III trials. These achievements have raised new challenges and further prospects, which are discussed. Patients with CAD requiring therapy should be considered for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.